Pyramid Analytics Ascends to the Large / Enterprise-Wide Implementations Category in BARC BI & Analytics 22 Report
11.11.2021 16:00:00 EET | Business Wire | Press release
Pyramid Analytics announced today that BARC (Business Application Research Center), a leading European analyst firm, elevated Pyramid’s Decision Intelligence Platform to the Large/Enterprise-Wide Implementations category. Pyramid received 40 Top Rankings (1st place) and 87 Leading Positions (place top 22-33% or top 2 products in its 6 peer groups) in The BI & Analytics Survey 22. Based on a sample of 2,478 survey responses, the BARC report offers an unsurpassed level of user feedback on 30 leading business intelligence (BI) solutions. BARC is one of Europe’s leading analyst firms for business software, focusing on the areas of data, business intelligence and analytics (ABI).
Key Points:
- 100 percent of customers surveyed would recommend Pyramid Analytics.
- 97 percent of users rate Pyramid’s functionality for creating dashboards as excellent or good, beating the average rating by 82 percent.
- 91 percent of users rate Pyramid Analytics’ vendor support as excellent or good. This is in sharp contrast with just 65 percent for the average BI tool.
- 88 percent of users rate Pyramid Analytics’ price to value as excellent or good; notably higher than the 71 percent for average tools.
- Download the complimentary report.
BARC Net Assessment
“It has been another great year for Pyramid Analytics, scoring 40 top ranks and 87 leading positions across its six peer groups. Pyramid performed especially well in comparison to its rivals in the Large/Enterprise-Wide Implementations peer group, where half of its top ranks came,” the report’s authors wrote, adding that “Pyramid customers clearly benefit from using the software. We asked customers to rate their level of achievement of 11 different business benefits. Pyramid scored well above average in almost all these benefits. Compared to other vendors in the survey, Pyramid customers are especially likely to be able to reduce costs, improve customer satisfaction, and improve operational efficiency.”
BARC determined that the Pyramid Analytics Decision Intelligence Platform deployments, use cases, functionality, and performance met its requirements for Enterprise-Wide Implementations; is well-suited to support a broad range of BI and analytics use cases and large numbers of end-users in multiple roles; and is capable of managing Big Data without compromising critical factors such as query response time, flexible self-service, and ease of use.
Complete, Integrated Decision Intelligence
Only Pyramid’s Decision Intelligence Platform unifies Data Preparation, Business Analytics, and Data Science on a single, integrated platform. This eliminates the need to use disparate, multiple tools and the associated license cost and management complexity. Lower Total Cost of Ownership (TCO), rapid rollout, and industry-leading user adoption means faster time to value.
The Pyramid Analytics Decision Intelligence Platform can be deployed on-premises, into a private or public cloud, embedded into other apps from Original Equipment Manufacturers (OEM) and Independent Software Vendors (ISV) or delivered through Managed Services Providers (MSP).
Voice of the Customer
- “A powerful platform with an abundance of well-thought out, integrated features and functionality. Fast, modern and sophisticated without being complicated.” Head of BI & Analytics Competence Center, Retail Industry, >2,500 employees
- “A polished product supported by an enthusiastic and knowledgeable team.” CIO, Energy Industry, >2,500 employees
- “A great product. Flexible and excellent self-service [BI & Analytics].” BI/Analytics Leader, Manufacturing Industry, >2,500 employees
Quotes
- Carsten Bange, Founder and CEO, BARC: “If you are considering buying a BI product, you really need to know how other users and organizations rate it. The BI & Analytics Survey 22 captures what end users really think about the BI products they use. Input from Pyramid Analytics customers and our own assessment of its ABI platform revealed continued innovation. Pyramid Analytics is a growing vendor with an increasing presence in the market. Its product is highly competitive, as the results in The BI & Analytics Survey 22 show. It is therefore unsurprising to see it has a high win rate when competing for new deals. I am eager to watch their progress over the next year.”
- Omri Kohl, CEO & Co-Founder, Pyramid Analytics: “We place tremendous value on The BI & Analytics Survey because BARC provides a painstakingly thorough analysis and, importantly, draws from real-world, hands-on experience. I thank Carsten and his team for their diligent research. And I am proud that the Pyramid Analytics Decision Intelligence Platform is again top-ranked or in a leadership position in all categories that mean the most to enterprise customers.”
Download a complimentary copy of Pyramid highlights in The BI & Analytics Survey 22 from BARC now.
About The BI & Analytics Survey 22
The BI & Analytics Survey 22 was conducted by BARC from March to June 2021. Altogether, 2,487 respondents worldwide answered a series of questions about their BI and analytics software. The survey offers a comparison of 30 leading business intelligence tools across 36 key performance indicators including Business Value, Customer Satisfaction, Customer Experience and Competitiveness. For more information, go to www.bi-survey.com.
About Pyramid Analytics
The Decision Intelligence Platform from Pyramid Analytics enables enterprises in any industry to maximize the value of data by unifying Data Preparation, Business Analytics, and Data Science in a single Analytics and Business Intelligence (ABI) infrastructure. By balancing performance and ease of use, everyone from business users to the most advanced data scientists get real-time, direct self-service access to reliable data from any domain or source, customized reports, and clear, actionable analysis. Flexible deployment options include on-premises and multi-cloud and hybrid environments. Schedule a demo.
Pyramid Analytics has offices in global innovation and business centers, including Amsterdam, London, New York City (US HQ), and Tel-Aviv, Israel. Our team lives worldwide because geography should not be a barrier to talent and opportunity. Learn more at Pyramid Analytics.
The Pyramid Decision Intelligence Platform. Know What’s Next.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211111005534/en/
Contact information
Chas Kielt
Vice President of Corporate Communications | Product and Partner Marketing, Pyramid Analytics
617.687.3371
chas.kielt@pyramidanalytics.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
